Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Glatz, M; Fingerle, V; Wilske, B; Ambros-Rudolph, C; Kerl, H; Müllegger, RR.
Immunoblot analysis of the seroreactivity to recombinant Borrelia burgdorferi sensu lato antigens, including VlsE, in the long-term course of treated patients with erythema migrans.
Dermatology. 2008; 216(2):93-103
Doi: 10.1159/000111505
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Glatz Martin
- Muellegger Robert
- Co-Autor*innen der Med Uni Graz
- Ambros-Rudolph Christina
- Kerl Helmut
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVE: We evaluated whether immunoblotting is capable of substantiating the posttreatment clinical assessment of patients with erythema migrans (EM), the hallmark of early Lyme borreliosis. METHODS: In 50 patients, seroreactivity to different antigens of Borrelia burgdorferi sensu lato was analyzed by a recombinant immunoblot test (IB) in consecutive serum samples from a minimum follow-up period of 1 year. Antigens in the IgG test were decorin-binding protein A, internal fragment of p41 (p41i), outer surface protein C (OspC), p39, variable major protein-like sequence expressed (VlsE), p58 and p100; those in the IgM test were p41i, OspC and p39. Immune responses were correlated with clinical and treatment-related parameters. RESULTS: Positive IB results were found in 50% before, in 57% directly after therapy and in 44% by the end of the follow-up for the IgG class, and in 36, 43 and 12% for the IgM class. In acute and convalescence phase sera, VlsE was most immunogenic on IgG testing (60 and 70%), and p41i (46 and 57%) and OspC (40 and 57%) for the IgM class. By the end of the follow-up, only the anti-p41i IgM response was significantly decreased to 24%. CONCLUSIONS: No correlation was found between IB results and treatment-related parameters. Thus, immunoblotting does not add to the clinical assessment of EM patients after treatment.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Anti-Bacterial Agents - therapeutic use
- Antibodies, Anti-Idiotypic - immunology
- Antibodies, Bacterial -
- Antigens, Bacterial - immunology
- Bacterial Proteins - immunology
- Borrelia burgdorferi - immunology
- Child -
- Enzyme-Linked Immunosorbent Assay -
- Erythema Chronicum Migrans - drug therapy
- Female -
- Follow-Up Studies -
- Humans -
- Immunoblotting - methods
- Immunoglobulin G - immunology
- Immunoglobulin M - immunology
- Lipoproteins - immunology
- Male -
- Middle Aged -
- Retrospective Studies -
- Time Factors -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- lyme borreliosis
- Borrelia burgdorferi
- immunoblot
- erythema migrans
- variable major protein-like sequence expressed antigen